Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial
Version of Record online: 27 OCT 2003
Volume 92, Issue 7, pages 741–747, November 2003
How to Cite
Homma, Y., Paick, J.S., Lee, J.G., Kawabe, K. and the Japanese and Korean Tolterodine Study Group (2003), Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International, 92: 741–747. doi: 10.1046/j.1464-410X.2003.04468.x
- Issue online: 27 OCT 2003
- Version of Record online: 27 OCT 2003
- Accepted for publication 28 May 2003
- 12Prevalence of overactive bladder in Asian males. International Continence Society. Seoul, Korea 2001 http://www.continet.org, , .
- 16Development of Japanese version of QOL questionnaires for urinary incontinence. Jpn J Neurogenic Bladder 1999; 10: 225 – 36, , , .
The results in this report are relevant only in those countries in which the once-daily form of oxybutynin is unavailable. The once-daily form, because of less first-pass liver metabolism, has fewer side-effects than the immediate-release form, and represents the ‘reference standard’ of oral oxybutynin therapy . Noteworthy in this article are: (i) the lack of any significant difference in efficacy variables between the active drugs; (ii) the presence of a difference in side-effect profile (dry mouth particularly); and (iii) the relatively small difference in efficacy variables between both active drugs and placebo, yet accounting for significant differences in quality of life. There is now a published direct comparison of the once-daily oral forms of tolterodine and oxybutynin . Although both relieve symptoms and have fewer side-effects than the once-daily counterparts, it is clear that newer forms of pharmacological therapy, directed either at inhibiting cholinergic activation of the detrusor with greater efficacy and/or tolerability, or at inhibiting different motor or sensory mechanisms, would be welcome for the treatment of OAB.
A.J. WEIN, MD, Professor & Chair, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA, USA
- 1Neuromuscular dysfunction of the lower urinary tract and its treatment. In WalshP, RetikA, VaughanED Jr, WeinAJ eds, Campbell's Urology. Eighth Edn. Philadelphia: WB Saunders, 2002: 931 – 66.